Item 2.02 Results of Operations and Financial Condition.

On March 25, 2021, 4D Molecular Therapeutics, Inc. ("4DMT") announced its audited financial results for the year ended December 31, 2020. A copy of 4DMT's press release, titled "4D Molecular Therapeutics Reports Financial Results for the Year Ended December 31, 2020 and Provides Operational Highlights," is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto.

Item 9.01 Financial Statements and Exhibits.






Exhibit No.                                  Description

99.1                Press Release, dated March 25, 2021, titled "4D Molecular
                  Therapeutics Reports Financial Results for the Year Ended
                  December 31, 2020 and Provides Operational Highlights"

The information in this report, including the exhibit hereto, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by 4DMT, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses